Here's Why Pfizer Stock Is Still a Buy

Pfizer, whose stock has fallen more than 50% from its 2021 peak after COVID-vaccine-driven exuberance waned, faces near-term pressure from imminent patent cliffs and the abandonment of an internally developed GLP-1 weight-loss drug. Management has pursued mitigation steps—buying a company with a GLP-1 pipeline and agreeing to distribute a Chinese firm's GLP-1 therapy—and the shares have rebounded roughly 20% from a 52-week low in early April. The stock yields about 6.7%, but that reflects a 100% reported payout ratio and a meaningful risk of a dividend cut, making the situation a turnaround story better suited for long-horizon, risk-tolerant investors.

Analysis

Market structure: Winners are GLP-1 leaders (Novo Nordisk NVO, Eli Lilly LLY) and smaller biotech targets with GLP-1 assets; generics makers (e.g., TEVA) win when Pfizer patent revenues drop. Losers are Pfizer (PFE) near-term pricing power and any vaccine-reliant suppliers as COVID demand normalizes. The shift reallocates pricing power toward companies with late-stage GLP-1 franchises; expect sustained demand for GLP-1s and tighter supply for active ingredients over 12–36 months.

Risk assessment: Tail risks include a major GLP-1 trial failure or FDA/China regulatory rejection of partner drugs, a >25% dividend cut, or adverse patent-litigation rulings that accelerate generic erosion; probability low–medium but impact high. Near-term (days–weeks) drivers are earnings and guidance; short-term (3–12 months) drivers are M&A integration and 1–2 expected readouts; long-term (1–3 years) is the patent cliff payoff. Hidden dependency: material revenue could hinge on third-party China distribution terms and milestones, not organic R&D.

Trade implications: Constructive but cautious stance — PFE is a turnaround candidate with asymmetric outcomes. Use capital-efficient, protected exposure (collar or long-dated call spread) rather than outright naked long. Rotate equal-weight from vaccine-exposed names into diversified big-cap pharms (MRK, JNJ) and GLP-1 winners (NVO/LLY) to capture secular growth while hedging patent risk.

Contrarian angles: Consensus underestimates speed at which Pfizer can monetize acquisitions/distribution deals and cut costs; downside priced for a worst-case that likely exceeds probability. Reaction appears somewhat overdone: a successful mid-stage GLP-1 readout or a single accretive bolt-on M&A could re-rate PFE by 20–40% over 12–24 months. Unintended consequence: activist-driven asset sales could unlock value but create short-term earnings volatility.

Key Decisions for Investors

• Establish a 3% portfolio long position in PFE (12–24 month horizon) using a collar: buy shares, sell 3‑6 month calls 5%–10% OTM, and buy 12‑month puts ~20% OTM to cap downside; trim if dividend cut >25% or FY guidance (-) >10%.
• Enter a 2% long / 2% short pair trade: long LLY or NVO (pick one with better 12‑month catalysts) and short PFE to express GLP‑1 outperformance; target relative outperformance of 15% in 6–12 months or stop if spread narrows <5% after 90 days.
• Buy a cheap upside convexity position: purchase PFE 9–12 month call spread (e.g., 15%–30% OTM) sized to 1–2% portfolio risk to capture recovery if a GLP‑1 asset or accretive M&A news arrives; cut if no positive readouts or deals within 12 months.
• Reduce small/mid‑cap vaccine/recovery‑exposed pharma exposure by 25% and reallocate to MRK/JNJ (overweight by +3% each) and to NVO/LLY (combined +3%) to favor pipeline diversity and GLP‑1 secular growth through 2026–2028.